Trials / Completed
CompletedNCT04752644
Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults
A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MVA-mBN294B | MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml. |
| DRUG | Placebo | TBS (Placebo) as intramuscular injections (0.5ml) |
Timeline
- Start date
- 2021-02-22
- Primary completion
- 2021-06-17
- Completion
- 2021-11-02
- First posted
- 2021-02-12
- Last updated
- 2023-07-21
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04752644. Inclusion in this directory is not an endorsement.